Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cabaletta Bio, Inc. (Nasdaq: CABA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, Cabaletta Bio uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and key developments in its RESET™ clinical program for rese-cel (resecabtagene autoleucel).
Investors reviewing Cabaletta Bio’s filings can find details on quarterly and annual financial performance, including research and development and general and administrative expenses, as well as information on public offerings used to fund clinical and commercial readiness activities. Current reports on Form 8-K often furnish press releases that summarize clinical data from the RESET-Myositis™, RESET-SSc™, RESET-SLE™, RESET-MG™ and RESET-PV™ trials, describe regulatory interactions with the U.S. Food and Drug Administration, and outline registrational cohort designs for rese-cel in specific autoimmune indications.
Filings may also discuss regulatory designations granted to rese-cel, such as Regenerative Medicine Advanced Therapy and Fast Track designations, and PRIME access from the European Medicines Agency, along with updates on chemistry, manufacturing and controls activities and collaborations, including the use of Cellares’ automated Cell Shuttle™ and Cell Q™ platforms for clinical manufacturing and quality control testing. These disclosures help readers understand how Cabaletta Bio is preparing for potential Biologics License Application submissions and future commercialization.
On Stock Titan, Cabaletta Bio’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the contents of lengthy reports, such as annual reports on Form 10-K or quarterly reports on Form 10-Q. Users can also monitor Form 8-K filings for material clinical, regulatory or financing events related to rese-cel and the broader CABA™ platform. This page is a resource for analyzing Cabaletta Bio’s regulatory history, financial condition and key milestones in its autoimmune-focused cell therapy programs.
Cormorant Asset Management, LP and Bihua Chen reported beneficial ownership of 5,000,000 shares of Cabaletta Bio common stock, equal to 5.47% of the outstanding class. The filing attributes sole voting and dispositive power of these shares as 0 and shared voting and dispositive power as 5,000,000. The shares are held by the Cormorant Funds and the filing identifies Cormorant Global Healthcare Master Fund, LP as having rights to more than 5% of the referenced shares. The ownership percentage is calculated using 91,465,233 shares outstanding as reported as of August 1, 2025. The filers certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing control, and they submitted a joint filing statement accepting responsibility for their portions of the disclosure.
Adage Capital Management, L.P. and affiliated reporting persons disclose beneficial ownership of 9,002,580 shares of Cabaletta Bio common stock, representing 9.99% of the outstanding class. The reported total includes 172,822 shares issuable upon exercise of warrants held by Adage's affiliate and is calculated using 89,943,101 shares reported outstanding in the company's prospectus.
The filing identifies Robert Atchinson and Phillip Gross as reporting persons and lists Adage as investment manager for Adage Capital Partners with a business address at 200 Clarendon Street, Boston. The cover rows show 0 shares of sole voting or dispositive power and 9,002,580 shares of shared voting and dispositive power. The reporting persons certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
In this Schedule 13G/A, Steven Nichtberger reports beneficial ownership of 3,034,499 shares of Cabaletta Bio common stock, representing approximately 3.3% of the outstanding class. The total comprises 986,483 shares held directly (about 1.1%), 363,000 shares held by the 2017 Nichtberger Family Trust (about 0.4%), and 1,685,016 shares underlying options exercisable within 60 days (about 1.8%).
The filing states Dr. Nichtberger has sole voting and dispositive power over all 3,034,499 shares. The reported percentages were calculated using 91,451,899 outstanding shares plus the exercisable options deemed outstanding under SEC rules. The filing indicates no shared voting power, no group affiliation, and no holdings reported on behalf of others.
Cabaletta Bio’s Q2-25 10-Q shows an enlarged pipeline but a materially higher cash burn. Operating expenses jumped 52% YoY to $45.9 M, driven by a 61% rise in R&D as the company advanced its CD19 CARTA program rese-cel across five autoimmune indications. The quarterly net loss widened to $45.1 M (-$0.73/sh) from $27.6 M (-$0.56/sh) one year ago; six-month loss reached $81.1 M.
Liquidity improved through an equity/warrant raise but a going-concern warning remains. In June the company issued 39.2 M shares plus 10.8 M pre-funded warrants, netting $93.6 M; an additional $2.6 M was raised via ATM sales. Cash & cash equivalents fell to $145.6 M but were supplemented by $49.1 M of new U.S. Treasury investments, lifting total cash & investments to $194.7 M. Lease-related assets boosted total assets to $224.5 M while finance lease liabilities rose to $20.3 M. Despite the capital infusion, management states that current resources “may not be sufficient” for 12 months, citing substantial doubt about going concern; cash burn from operations was $61.2 M in 1H-25.
Prudential Financial, Inc. (PFI) has filed Amendment No. 2 to Schedule 13G for Cabaletta Bio, Inc. (NASDAQ: CABA). As of 30 June 2025, PFI reports beneficial ownership of 10,391,167 common shares, representing 7.4 % of CABA’s outstanding stock. All shares are held with shared voting and dispositive power; PFI claims no sole authority over the shares.
The position is held through two investment-management subsidiaries: Jennison Associates LLC (10,107,167 shares; 7.2 %) and PGIM, Inc. (284,000 shares; 0.2 %). PFI classifies itself as a “parent holding company/ control person” under Rule 13d-1(b)(1)(ii)(G) and certifies the shares are held in the ordinary course of business, not to influence control of Cabaletta Bio.
Key takeaways for investors: 1) PFI remains a >5 % holder, indicating continued institutional support; 2) the stake size affords PFI meaningful, though not controlling, influence in shareholder matters; 3) no sale intention or activist purpose is disclosed.
Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company’s 92.94 million shares outstanding.
Citadel Advisors–managed funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
